IMG-7289 for Essential Thrombocythemia

Overseen By Epp Goodwin

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: The University of Texas Health Science Center at San Antonio

Must be taking: Hydroxyurea

Must not be taking: MAOIs

Disqualifiers: Pregnancy, HIV, Hepatitis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

9 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

Who Is on the Research Team?

Zohra Nooruddin, MD

Principal Investigator

Mays Cancer Center

Are You a Good Fit for This Trial?

Adults diagnosed with Essential Thrombocythemia who have high platelet counts despite hydroxyurea treatment, can swallow capsules, and will use contraception. Excluded are those with unresolved toxicities from past treatments, active infections including HIV/hepatitis, bleeding risks, pregnancy/breastfeeding plans within six months or current breastfeeding.

Inclusion Criteria

I can swallow pills.

Peripheral blast count <10% pre-dose Day 1

I agree not to father a child or donate sperm for a month after my last dose.

Exclusion Criteria

I need considerable assistance and am unable to carry out any work activities.

I have had more than 3 blood transfusions in the last 6 months or any transfusion in the last 4 weeks.

You have signs that show you might have a higher chance of bleeding, such as:

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive IMG-7289 orally once daily

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• IMG-7289

Trial Overview The trial is testing the oral drug IMG-7289 for patients with Essential Thrombocythemia. It's an open-label study where all participants know they're receiving the medication to see how it affects their condition.

How Is the Trial Designed?

Group I: IMG-7289 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

The University of Texas Health Science Center at San Antonio

Lead Sponsor

Trials

486

Recruited

92,500+

Imago BioSciences,Inc.

Industry Sponsor

Trials

10

Recruited

380+

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Industry Sponsor

Trials

10

Recruited

380+